UbiVac
Blood & Organ Banks · Oregon, United States · 11-50 Employees
View Company Info for Free
Overview
Headquarters
18183 SW Boones Ferry Rd, Portland, Oreg...Phone Number
(503) 292-4066Website
www.ubivac.comRevenue
<$5 MillionIndustry
ZI Rank: 1
Signal Type
Dec
Jan
Feb
Mar
Apr
May
ZI Rank
1
1
1
2
2
1
About UbiVac
UbiVac is a clinical stage immunotherapy and cancer target discovery company pioneering the world's first Dark Genome-derived cancer immunotherapy. Their lead agent, DPV-001, utilizes non-mutated shared alternative cancer neoantigens to stimulate immune responses in patients with advanced cancers. UbiVac targets patients with adenocarcinoma or squamous cell cancers, aiming to improve treatment outcomes through innovative vaccine technology and collaborations with leading research institutes. The company is positioned as a leader in non-canonical target discovery, developing next-generation cancer vaccines and therapies based on real-world immunogenicity.Explore more
UbiVac Org Chart
Sell smarter with deeper company insights.
ZoomInfo gives you access to real-time firmographics, buying signals, org charts, and decision-makers - helping your GTM teams prioritize accounts, personalize outreach with AI-driven automation, and close deals faster.
Is UbiVac your ideal customer? 
Let us give you the heads up on whether it's a good time to reach out
UbiVac, which may be a good buyer, showed buying intent in Masked Content Topic
Congratulate Masked Content for being promoted to Masked Content at UbiVac
Click to see if UbiVac had a recent Job posting/layoffs
Funding: Get notified immidiatlly once UbiVac has new funding data
Product Launch: Get notified when UbiVac launches new products
Competitive Alert! Recent activity has been detected by your competitor Masked Content
Check out if UbiVac is spiking on competitors!
Check if UbiVac has recently received funding, and reach out quickly before it becomes old news!
Website visits: Recent activity has been detected on your website
Earning: See what the market has to say on UbiVac recently announced quarterly report
Recommended Actions
Reach out to Masked Content who joined UbiVac as Masked Content
Find more new buyers
Compare Similar Companies to UbiVac
Compare insights from companies similar to UbiVac, focusing on performance, financial data, growth rates, and unique benchmarks to identify key industry trends and opportunities.
Revenue
Number of Employees
Type
Funding
Founded In
Company Profile Activity
Activity Insights
UbiVac is experiencing very low activity levels compared to other companies in the Healthcare Services sector.
What does this means?
UbiVac is drawing exceptional interest within the Healthcare Services industry, suggesting notable developments or strong market momentum, learn more about UbiVac.
UbiVac Tech Stack
A closer look at the technologies used by UbiVac
UbiVac News & Media
UbiVac CEO Presents Pioneering Dark-Matter Cancer Vaccine Advances at Parker Institute for Cancer Immunotherapy Workshop
Clinical Data Show DPV-001 Combo immunotherapy Triples Response Rates, PFS, and Doubles Overall Survival Over Standard of Care NEW YORK, NY, UNITED STATES, November 17, 2025 /EINPresswire.com/ -- UbiVac, www.ubivac.com, a private, clinical-stage Immuno- …UbiVac Showcases First 'Dark Matter' Cancer Immunotherapy Data at SITC 2025
DPV-001, first cancer vaccine derived from the human dark genome, shows improved survival in head and neck cancer and reveals more than 400 new antigen targets. NATIONAL HARBOR, MD, UNITED STATES, November 10, 2025 /EINPresswire.com/ -- UbiVac, https:// …UbiVac to present on Dark Genome-derived Dark Matter/Proteome Cancer Immunotherapy at Spring 2025 Venture Forum
UbiVac's DPV-001 is the World's 1st Dark Matter Cancer Immunotherapy in the Clinic - Promising Early Data Supports Phase II Trial PORTLAND, OR, UNITED STATES, March 19, 2025 /EINPresswire.com/ -- UbiVac, www.ubivac.com, a private, clinical-stage …Promising Phase Ib Data for UbiVac’s DPV-001 in Combination Immunotherapy for Head and Neck Squamous Cell Cancer
UbiVac's DPV-001 Dark Matter combo Immunotherapy triples response rate and progression-free survival over PD-1 alone for patients with r/m head and neck cancer HOUSTON, TX, UNITED STATES, November 7, 2024 /EINPresswire.com/ -- UbiVac, www.ubivac.com …
Read more news
Top Blood & Organ Banks Companies
Top companies in Canada by revenue
Top companies in Australia by revenue
Top companies in New Zealand by revenue
Frequently Asked Questions Regarding UbiVac
Sign Up For FreeTo access detailed company insights
UbiVac is a clinical stage immunotherapy and cancer target discovery company pioneering the world's first Dark Genome-derived cancer immunotherapy. Their lead agent, DPV-001, utilizes non-mutated shared alternative cancer neoantigens to stimulate immune responses in patients with advanced cancers. UbiVac targets patients with adenocarcinoma or squa... Read More
